Stockscreener 앱 받기
4.74
0.22%
0.05
시간 외 거래:
4.74
전일 마감가:
$4.69
열려 있는:
$4.66
하루 거래량:
497.63K
Relative Volume:
0.36
시가총액:
$616.12M
수익:
$204.17M
순이익/손실:
$-74.00M
주가수익비율:
-8.2078
EPS:
-0.5775
순현금흐름:
$-12.84M
1주 성능:
+0.87%
1개월 성능:
+1.74%
6개월 성능:
+11.91%
1년 성능:
+17.22%
1일 변동 폭
$4.57
$4.76
1주일 범위
$4.53
$4.935
52주 변동 폭
$3.28
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
명칭
Cytek Biosciences Inc
전화
(877) 922-9835
주소
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.74 | 609.62M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
110.36 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
331.66 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.60 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.45 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.81 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-09 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-31 | 다운그레이드 | Goldman | Buy → Sell |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-07-19 | 개시 | Raymond James | Mkt Perform |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
모두보기
Cytek Biosciences Inc 주식(CTKB)의 최신 뉴스
Cytek (CTKB) Q2 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer - Stock Titan
Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments - Pulse 2.0
Cytek Biosciences launches Aurora Evo system to drive high-throughput research and small particle detection - Traders Union
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Cytek Biosciences (NASDAQ:CTKB) Trading 8.5% HigherShould You Buy? - marketbeat.com
Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Cytek Biosciences, Inc. (CTKB) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A - Stock Titan
Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Cuts Target Price to $5 - Moomoo
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ... - Yahoo! Finance Canada
Cytek Biosciences Q2 2026 Earnings Report: Financial Highlights, Revenue Growth, and Investor Insights - Minichart
CTKB Looks 28.3% Undervalued on GF Value™ Despite Unprofitable S - GuruFocus
Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Hits Estimates - marketbeat.com
Cytek Biosciences Q2 Earnings Call Highlights - MarketBeat
Cytek Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cytek Biosciences earnings missed, revenue fell short of estimates - Investing.com
Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall - Investing.com Nigeria
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
Cytek Biosciences, Inc. 2Q 2026: Revenue $48.14M, EPS ($0.09) — 10-Q Summary - TradingView
Cytek Biosciences Q2 2026: Revenue $48.1M, Gross Profit $28.3M, Net Loss $12.2M - TradingView
Cytek Biosciences, Inc. Raising Revenue Guidance for the Full Year 2026 - marketscreener.com
Cytek Biosciences Reports Second Quarter 2026 Financial Results - The Manila Times
Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million - Bitget
Cytek Biosciences (CTKB) Dips 2.3% to $4.18 as Support at $3.97 Comes into FocusMA Cross Alert - dars.gov.et
Cytek Biosciences incentivizes larger reagent purchases with free summer gifts - Traders Union
Boston Partners (CTKB) discloses 7.64M-share beneficial stake in Cytek Biosciences - stocktitan.net
Cytek Biosciences, Inc. expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cytek Biosciences (CTKB) Expected to Release Quarterly Earnings on Wednesday - marketbeat.com
Cytek Biosciences, Inc. Revenue Breakdown – TRADEGATE:8EQ - TradingView
Cytek Biosciences Inc (CTKB) Cash Flow - TradingKey
Cytek Biosciences Inc (CTKB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytek Biosciences Inc (CTKB) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
CTKB|Cytek Biosciences Inc|Price:4.420|Chg%:-0.040 - TradingKey
Cytek Biosciences, Inc. Revenue Breakdown – FWB:8EQ - TradingView
Cytek Biosciences Inc (CTKB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cytek Biosciences (CTKB) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Shares SlipROE Trend Analysis - po-news-eg.net
Cytek Biosciences CEO advances flow cytometry for informed healthcare decision making - Traders Union
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? - TradingView
CTKB stock rises as Cytek BioSciences reports revenue and margin trends - Ad-hoc-news.de
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Cytek Biosciences to report Q2 2026 results on August 5 - scanx.trade
Cytek Biosciences sets Q2 results call for 4:30 p.m. ET Aug. 5 - Stock Titan
Cytek Biosciences reveals special summer incentive for reagent customers - Traders Union
Cytek Bio stock trades steadily as Q1 2026 growth and margin profile frame investor focus - Ad-hoc-news.de
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement - BioSpace
Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement - Finviz
Cytek Biosciences Inc (CTKB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
자본화:
|
볼륨(24시간):